CStone Pharmaceuticals' (HKG:2616) sugemalimab has been included in the European Society for Medical Oncology (ESMO) Non-Oncogene-Addicted Metastatic Non-Small-Cell Lung Cancer Living Guideline, a Monday bourse filing said.
Sugemalimab is recommended as a first-line combination therapy for both squamous and non-squamous non-small-cell lung cancer.
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.